Search results
Mar 20, 2024 · Here, we developed a monoclonal antibody (mAb2A7) against 217 site-phosphorylated human tau (p-tau217) and observed that p-tau217 levels positively correlated with brain atrophy and cognitive impairment in AD patients.
May 15, 2024 · tau Proteins. Neuronal loss is the central issue in Alzheimer's disease (AD), yet no treatment developed so far can halt AD-associated neurodegeneration. Here, we developed a monoclonal antibody (mAb2A7) against 217 site-phosphorylated human tau (p-tau217) and observed that p-tau217 levels positively correlated w ….
Apr 11, 2024 · It might also be a good therapeutic target, say scientists led by Yingjun Zhao at Xiamen University in China. In the March 20 Neuron, they reported that tauopathy mice given an antibody, dubbed mAb2A7, against p-Tau217 had fewer tangles, less neurodegeneration, and better memory and motor function.
May 15, 2024 · The reverted proteins resulting from the P19-mAb2A7 treatment are defined as the overlapping differentially expressed proteins (DEPs) between the PS19-mAb2A7 vs. PS19-IgG comparison and the PS19-IgG vs. WT-IgG comparison, exhibiting reversed expression changes in two contrasts.
Alzheimer's disease (AD) is the most common neurodegenerative disease characterized by cognitive impairment with few therapeutic options. Despite many failures in developing AD treatment during the past 20 years, significant advances have been achieved in passive immunotherapy of AD very recently.
Mar 7, 2018 · Here we found that TREM2 directly binds to β-amyloid (Aβ) oligomers with nanomolar affinity, whereas AD-associated TREM2 mutations reduce Aβ binding. TREM2 deficiency impairs Aβ degradation in primary microglial culture and mouse brain.
Nov 16, 2022 · Zhao XY, Yu XX, Xu ZL, Cao XH, Huo MR, Zhao XS, et al. Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantation. Blood Adv 2019, 3, 4312–25. doi: 10.1182/bloodadvances.2019000242. [PMC free article] [Google Scholar]
